Total Nutrition Inc. Recalls Moringa Capsules Across Four Retail Channels After FDA Salmonella Alert

A voluntary recall of botanical supplement capsules by Total Nutrition Inc. of Deer Park, NY underscores a persistent microbial contamination risk in natural-origin ingredient sourcing, one with direct relevance to pharmaceutical manufacturers relying on plant-derived excipients or APIs. The recall, initiated May 26, 2026, covers TNVitamins Ultra Potent Complete Green Superfood and Doctor's Pride Complete Green Superfood Ultra Potent Moringa Capsules (120-count) across four specific lots, following notification from the FDA and CDC linking the products to an ongoing investigation into moringa-containing dietary supplements.

The trigger was potential Salmonella contamination, a pathogen that presents serious infection risk in immunocompromised individuals, the elderly, and young children, and can progress to systemic illness including endocarditis and arterial infection. Affected lots span two product lines: TNVitamins (Lots 2507199, 2512-304, 2793) and Doctor's Pride (Lot 2507199), with expiry dates running through February 2028. Distribution reached national scale via Amazon, Walmart, Target, TikTok Shop, and the company's own e-commerce platforms, a fulfillment footprint that complicates field correction logistics considerably.

For QA directors and supply-chain leads in pharmaceutical manufacturing, the contamination vector is instructive. Moringa is a botanical raw material with documented susceptibility to microbial load at the cultivation and post-harvest processing stages. Where pharma operations source natural-origin excipients, cellulose derivatives, plant-based binders, herbal APIs, incoming material testing protocols and supplier qualification frameworks carry equivalent risk exposure. 21 CFR Part 211.84 requires identity testing and, where appropriate, full specification testing of each lot of components; a risk-based argument for reduced testing frequency is harder to sustain when the ingredient class carries inherent microbial variability.

The recall was initiated following external notification rather than internal detection, a sequencing that warrants scrutiny under ICH Q10 pharmaceutical quality system principles, specifically around the robustness of incoming material release criteria and the adequacy of supplier audit cycles. Total Nutrition Inc. has ceased distribution, issued removal orders across all sales and fulfillment channels, and confirmed no other products in either brand are implicated.

The FDA and CDC investigation into the broader moringa supplement category remains open, and additional lot-level findings could expand the scope of affected products industry-wide before the inquiry closes.

Source: U.S. Food and Drug Administration, Recalls, Market Withdrawals and Safety Alerts, May 26, 2026.